ESMO Breast 2023

ESMO Breast Cancer Congress
11–13 May 2023 | Berlin, Germany
VJOncology avatar; VJ Oncology @VJOncology ·
October 1, 2023 1708391370291863912

📢Day 2 of #ICCN2023! Today, oncology nursing experts discuss the emotional and psychosocial effects of cancer, as well as the impact of treatments in cancer care and much more!

➡️Stay up-to-date with http://VJOncology.com

@ISNCC #CancerNursing #OncoRN

Image for the Tweet beginning: 📢Day 2 of #ICCN2023! Today, Twitter feed image.
Reply on Twitter 1708391370291863912 Retweet on Twitter 1708391370291863912 0 Like on Twitter 1708391370291863912 3 Twitter 1708391370291863912
VJOncology avatar; VJ Oncology @VJOncology ·
September 30, 2023 1708028989493645370

📢Day 2 of #ICCN2023! Today, oncology nursing experts will be discussing their role in improving the quality of cancer care, the challenges and initiatives in oncology nursing education, and mire!

Stay up-to-date with http://VJOncology.com

@ISNCC #CancerNursing #OncoRN

Image for the Tweet beginning: 📢Day 2 of #ICCN2023! Today, Twitter feed image.
Reply on Twitter 1708028989493645370 Retweet on Twitter 1708028989493645370 0 Like on Twitter 1708028989493645370 1 Twitter 1708028989493645370
VJOncology avatar; VJ Oncology @VJOncology ·
September 29, 2023 1707802543370207242

Did you know that September is Urological Cancer Awareness Month? 🤔

Listen to our podcast on #bladdercancer highlights from #ASCO23, including results from the THOR, NORSE, and RAGNAR trials!

Give it a listen 👉 https://ow.ly/xqKN50PGuT6

#Oncology #GUsm #PCsm #uroonc

Image for the Tweet beginning: Did you know that September Twitter feed image.
Reply on Twitter 1707802543370207242 Retweet on Twitter 1707802543370207242 1 Like on Twitter 1707802543370207242 0 Twitter 1707802543370207242
Load More

ESMO Breast 2023

ESMO Breast Cancer Congress
11–13 May 2023 | Berlin, Germany
The European Society for Medical Oncology (ESMO) Breast Cancer Conference was held in Berlin, Germany on the 11-17 May. This annual meeting delivered the latest updates in the breast cancer field.
VJOncology avatar; VJ Oncology @VJOncology ·
October 1, 2023 1708391370291863912

📢Day 2 of #ICCN2023! Today, oncology nursing experts discuss the emotional and psychosocial effects of cancer, as well as the impact of treatments in cancer care and much more!

➡️Stay up-to-date with http://VJOncology.com

@ISNCC #CancerNursing #OncoRN

Image for the Tweet beginning: 📢Day 2 of #ICCN2023! Today, Twitter feed image.
Reply on Twitter 1708391370291863912 Retweet on Twitter 1708391370291863912 0 Like on Twitter 1708391370291863912 3 Twitter 1708391370291863912
VJOncology avatar; VJ Oncology @VJOncology ·
September 30, 2023 1708028989493645370

📢Day 2 of #ICCN2023! Today, oncology nursing experts will be discussing their role in improving the quality of cancer care, the challenges and initiatives in oncology nursing education, and mire!

Stay up-to-date with http://VJOncology.com

@ISNCC #CancerNursing #OncoRN

Image for the Tweet beginning: 📢Day 2 of #ICCN2023! Today, Twitter feed image.
Reply on Twitter 1708028989493645370 Retweet on Twitter 1708028989493645370 0 Like on Twitter 1708028989493645370 1 Twitter 1708028989493645370
VJOncology avatar; VJ Oncology @VJOncology ·
September 29, 2023 1707802543370207242

Did you know that September is Urological Cancer Awareness Month? 🤔

Listen to our podcast on #bladdercancer highlights from #ASCO23, including results from the THOR, NORSE, and RAGNAR trials!

Give it a listen 👉 https://ow.ly/xqKN50PGuT6

#Oncology #GUsm #PCsm #uroonc

Image for the Tweet beginning: Did you know that September Twitter feed image.
Reply on Twitter 1707802543370207242 Retweet on Twitter 1707802543370207242 1 Like on Twitter 1707802543370207242 0 Twitter 1707802543370207242
Load More
MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence 1:29
MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence
Patrick Neven • 11 May 2023
Emerging toxicities associated with ADCs 2:07
Emerging toxicities associated with ADCs
Sung-Bae Kim • 11 May 2023
Personalized ctDNA during neoadjuvant therapy in pts with early-stage breast cancer 2:51
Personalized ctDNA during neoadjuvant therapy in pts with early-stage breast cancer
Mridula George • 12 May 2023
HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies 1:42
HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
Adrienne Waks • 12 May 2023
KEYNOTE-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated AEs 4:01
KEYNOTE-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated AEs
Hope Rugo • 12 May 2023
Exploring novel strategies for breast cancer treatment 0:57
Exploring novel strategies for breast cancer treatment
Sung-Bae Kim • 11 May 2023
Phase Ib data CAPItello-292: capivasertib + palbociclib + fulvestrant in HR+/HER2- breast cancer 1:49
Phase Ib data CAPItello-292: capivasertib + palbociclib + fulvestrant in HR+/HER2- breast cancer
Patrick Neven • 11 May 2023
Detailed safety analysis from the DESTINY-Breast04 trial 6:33
Detailed safety analysis from the DESTINY-Breast04 trial
Hope Rugo • 12 May 2023
HR status in determining the efficacy of platinum therapy in advanced TNBC 1:07
HR status in determining the efficacy of platinum therapy in advanced TNBC
Tira Tan • 12 May 2023
HER2DX risk-score in early-stage HER2-positive breast cancer 1:22
HER2DX risk-score in early-stage HER2-positive breast cancer
Guillermo Villacampa Javierre • 12 May 2023
Development of antibody-drug conjugate therapies in breast cancer 1:11
Development of antibody-drug conjugate therapies in breast cancer
Heather McArthur • 12 May 2023
Investigating the influence of HER2 low status in LBC 0:41
Investigating the influence of HER2 low status in LBC
Karen Van Baelen • 12 May 2023
ILC: a commonly overlooked subtype of breast cancer 1:17
ILC: a commonly overlooked subtype of breast cancer
Karen Van Baelen • 12 May 2023
Addressing the underrepresentation of ILC in clinical trials 0:43
Addressing the underrepresentation of ILC in clinical trials
Karen Van Baelen • 12 May 2023
Is it possible to predict who will benefit the most from IO in TNBC? 3:55
Is it possible to predict who will benefit the most from IO in TNBC?
Justin Balko • 12 May 2023
Prognostic biomarkers of immunotherapy efficacy in breast cancer 0:55
Prognostic biomarkers of immunotherapy efficacy in breast cancer
Justin Balko • 12 May 2023

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals